PBM
DAWN

Propel Bio Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Propel Bio Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-270,664
Closed -$4.47M – 25
2024
Q1 		$4.47M Hold
270,664
– – 2.6% 10
2023
Q4 		$3.95M Buy
+270,664
New +$3.28M 3.28% 9

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Propel Bio Management's DAWN Position: Q2 2024 in Review

Propel Bio Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2024, closing a stake of 270,664 shares — an estimated $4.47M sold.

Propel Bio Management first reported a position in DAWN in Q4 2023 and held it in 2 quarters. The position peaked at $4.47M in Q1 2024. 157 funds tracked by Wall St. Rank hold DAWN as of Q2 2024.

  • Propel Bio Management reported no remaining Day One Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Propel Bio Management sold 270,664 Day One Biopharmaceuticals shares in Q2 2024, an estimated $4.47M.
  • Propel Bio Management first reported a position in Day One Biopharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Propel Bio Management's Day One Biopharmaceuticals position peaked at $4.47M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2024.

Based on Propel Bio Management's 13F filing for Q2 2024, filed 12 Aug 2024.